Psoriasis

JDD August Issue Highlights
Here are the issue highlights and Editor Picks for the August issue of JDD: Clearance of psoriasis leads to greater uptake of cosmetic procedures in Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement. The Effect of Tildrakizumab on Cardiometabolic Two Phase 3 Trials (reSURFACE 1 and reSURFACE 2) examines the impact of IL-23 inhibition on c …
Methotrexate Therapeutic Cheat Sheet
Methotrexate injection for psoriasisIn this month’s installment of Therapeutic Cheat Sheet, we will review methotrexate and its use in dermatology. Methotrexate has been utilized as therapy for psoriasis and many other dermatologic conditions since its approval by the FDA in 1972.1 While an effective systemic agent for a multitude of dermatologic and non-dermatologic diseases, prescribers should be aware of the side effect profile …
Methotrexate injection for psoriasis
Patient Buzz Series: Pandemic and Protests
Patient Buzz SeriesConsumer news articles are revealing patients’ questions about the impact of the deadly pandemic and nationwide protests on their skin, hair, and nail health. How can you prevent breakouts from wearing face masks? Should you avoid oil-based beauty products while protesting? Is ‘COVID toe’ not actually caused by COVID-19? Be prepared for your patients’ questions about these timely dermat …
Patient Buzz Series
Inhibiting the JAK/STAT Pathway to Treat Inflammatory Skin Diseases
JAK InhibitorsNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Jonathan Zippin, Vice-Chair of Research and an Associate Attending Dermatologist and Associate Professor of Dermatology at Weill Medical College of Cornell, and Director of the Contact, Occupational and Photodermatitis Service. Watch as he reviews the JAK/STAT signaling pathway in normal i …
JAK Inhibitors
Coronavirus & Atopic Dermatitis Reporting Registry
SECURE-ADEPI Health has graciously supported the COVID-19 News and Resource Center. SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion - Atopic Dermatitis) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in atopic dermatitis (AD) patients. Clinicians worldwide are encouraged to report al …
SECURE-AD